Morgan Stanley downgrades iRhythm Technologies target price

Summary

Morgan Stanley has lowered the target stock price for iRhythm Technologies (NASDAQ: IRTC) from $160.00 to $147.00 while maintaining an ‘overweight’ rating. This new target suggests a 5.89% upside potential from the current stock price. Other analysts have differing views, with Citigroup raising the target to $167.00 and Needham to $151.00. The consensus rating for the stock is ‘moderate buy,’ with an average target price of $137.30. iRhythm’s recent quarterly report shows a 20.3% increase in revenue year-over-year despite an EPS loss of $0.95. Market Beat

Impact Analysis

The event is classified at the company level, focusing on iRhythm Technologies. Morgan Stanley’s decision to lower the target price might signal concerns regarding future growth or profitability. However, the ‘overweight’ rating still indicates positive expectations. This mixed sentiment from analysts can lead to varied investor reactions, potentially increasing volatility in the stock price. First-order effects include immediate market reactions to the new target price, as investors reassess their holdings. Second-order effects could involve changes in investor sentiment towards iRhythm Technologies, potentially influencing investment in the broader digital health sector. Opportunities may exist for investors who believe in the company’s long-term growth potential, particularly if they align with Citigroup’s more optimistic outlook. Risks include potential pressure on the stock if negative sentiment prevails. Market Beat+ 3